The Estrogen Patch: A Proven Alternative to ADT Injections
Estradiol Patch Matches LHRH Agonists for Locally Advanced Prostate Cancer | MedPage Today
Treatment Updates
Bottom Line Up Front (BLUF)
A large, 15-year British clinical trial—just published in the New England Journal of Medicine on March 25, 2026—shows that estradiol skin patches work just as well as the standard hormone-blocking injections for controlling locally advanced prostate cancer. The patches matched LHRH agonist shots for preventing metastasis and preserving life, while cutting hot flashes in half. The main tradeoff is a higher rate of breast tissue swelling (gynecomastia). For men who struggle with hot flashes, fatigue, or bone loss from conventional ADT, this evidence-backed alternative is now firmly on the table—and it costs a fraction of standard injections.
Background: What Is ADT and Why Does It Matter?
For men with locally advanced or metastatic prostate cancer, androgen deprivation therapy (ADT) — sometimes called hormone therapy — has been the foundation of treatment for more than 80 years. The goal is straightforward: drive testosterone down to "castrate levels" below 50 ng/dL, because prostate cancer cells are fueled by testosterone.
Today, the most common way to accomplish this is through regular injections of LHRH agonists (drugs like leuprolide/Lupron or goserelin/Zoladex). These drugs are highly effective. But they work by blocking the body's production of both testosterone and estrogen — and that estrogen deficit is responsible for some of the most disabling side effects many of you know all too well: crushing hot flashes, night sweats, bone loss, weight gain, metabolic changes, and deep fatigue.
Doctors once tried oral estrogen (in the form of diethylstilbestrol, or DES) to suppress testosterone, and it worked beautifully — until it caused dangerous blood clots in a significant percentage of patients, because oral estrogen passes through the liver and triggers clotting factors. Oral estrogen was largely abandoned for this reason.
But what if estrogen could be delivered in a way that bypasses the liver entirely?
The PATCH Trial: 15 Years in the Making
That was the idea behind the PATCH trial (Prostate Adenocarcinoma TransCutaneous Hormone trial, NCT00303784), launched in the United Kingdom in 2007. Researchers, led by Dr. Ruth Langley at University College London and Dr. Nicholas James at London's Royal Marsden Hospital, reasoned that transdermal estradiol patches — similar to the patches used in menopausal hormone therapy — absorb directly through skin into the bloodstream, bypassing the liver entirely and eliminating the clotting risk that doomed oral estrogen.
The PATCH trial eventually merged into the larger STAMPEDE platform trial (NCT00268476), one of the most ambitious prostate cancer research programs in the world. Together, they enrolled 1,360 men with locally advanced (non-metastatic, or M0) prostate cancer and randomized them either to estradiol patches or to standard LHRH agonist injections.
The results of that 15-year effort were published on March 25, 2026, in the New England Journal of Medicine — arguably the most prestigious medical journal in the world — representing a major milestone for this approach.
What the NEJM Study Found
The primary question was: do estradiol patches keep cancer from spreading (metastasis-free survival, or MFS) just as well as LHRH injections? The answer was a clear yes.
Three-year metastasis-free survival was 87.1% with estradiol patches versus 85.9% with LHRH agonists — a small difference that comfortably met the statistical standard for "non-inferiority." In plain language: the patches were just as good as the injections at preventing the cancer from spreading. Five-year overall survival also did not differ significantly between the two groups (81.1% vs. 79.2%), with a hazard ratio of 0.90 that slightly favored the patches, though confidence intervals were wide.
Both treatments achieved the same goal of castrate testosterone levels, maintained in 85% of patients in each group throughout the first year.
The Side Effect Tradeoffs
The differences between the two treatments lie not in cancer control, but in the kind of side effects they produce. This is where the choice becomes personal.
Hot flashes: This was the most dramatic difference. Hot flashes occurred in 44% of patch users versus 89% of LHRH users. Severe hot flashes (grade 2 or higher) affected only 8% of patch users compared to 37% of injection users. For many men, hot flashes and the resulting sleep disruption are the most disabling aspect of hormone therapy. The patches largely eliminated them.
Gynecomastia (breast tissue enlargement): The major tradeoff. Gynecomastia occurred in 85% of patch users versus 42% of injection users. Severe gynecomastia affected 37% of patch users vs. 9% of injection users. Breast swelling and soreness can be bothersome, though severity ranges widely. Strategies to manage gynecomastia are discussed below.
Bone density: A major long-term benefit of the patches. Prior sub-studies published in the PATCH program showed that while LHRH agonists caused an average 3% loss in lumbar spine bone mineral density, estradiol patches produced an average 7.9% gain — a nearly 11-point difference. This is enormous: STAMPEDE data show that men on long-term LHRH therapy face a 25% hospital admission rate for hip fractures at 10 years. The patches may largely eliminate that risk and the need for expensive bone-protective drugs like bisphosphonates.
Cardiovascular safety: Unlike the oral estrogen of decades past, no excess cardiovascular risk or thromboembolic events were observed with the patches in any of the PATCH/STAMPEDE analyses. In fact, multiple analyses found the patches associated with better metabolic profiles — including lower hypertension rates than LHRH agonists — which could be especially attractive for men with a history of cardiovascular disease.
Fatigue and quality of life: Dr. James, speaking at ASCO GU 2025, described the overall quality-of-life picture: less fatigue, better preservation of sexual interest, far fewer hot flashes, and improved bone density — with gynecomastia as the one area where patches fared worse.
Beyond M0 Disease: Results in Metastatic Patients
The NEJM paper focused on men with locally advanced, non-metastatic prostate cancer. But a companion study within the STAMPEDE platform asked whether the patches work when combined with the powerful second-line hormonal drugs known as androgen receptor pathway inhibitors (ARPIs) — drugs like abiraterone (Zytiga), enzalutamide (Xtandi), and apalutamide (Erleada) — in men with metastatic (M1) disease.
That STAMPEDE sub-study, presented by Dr. James at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco, randomized 79 metastatic patients to receive either LHRH + ARPI or estradiol patches + ARPI. Within six months, 61% of patients in each arm reached the target PSA nadir of ≤0.2 ng/mL — identical response rates. Hot flash rates again strongly favored the patches (5% grade 2 vs. 24%), as did hypertension rates (5% vs. 17%). Gynecomastia was again the main downside of the patch arm.
Dr. James concluded: "It's effective as measured here, it's safe. There were no safety signals for the interaction. We think it's an alternate therapy choice for men starting ADT."
Managing Gynecomastia: What Are the Options?
Gynecomastia (breast tissue swelling and tenderness) is the principal side effect that will influence whether a given man chooses patches over injections. Here is what the evidence says about managing it:
Prophylactic breast radiation: A single low dose of radiation to the breast tissue, given before gynecomastia develops, is significantly more effective than treating established gynecomastia. A randomized Scandinavian trial (SPCG-7/SFUO-3) showed that single-dose prophylactic breast irradiation reduced gynecomastia incidence from 71% to 28% and breast tenderness from 75% to 43%. Dr. Gilbert of the PATCH trial team noted that prophylactic irradiation is considerably more effective than treating the condition once it is established.
Prophylactic tamoxifen: A 2025 systematic review and meta-analysis published in European Urology Open Science found that prophylactic tamoxifen (a drug that blocks estrogen at the breast) reduces gynecomastia incidence to as low as 10% from 73% without treatment, with good overall tolerance. It appeared more effective than prophylactic radiation in direct comparison for the curative intent setting.
Note from the NEJM investigators: Radiation to treat established gynecomastia was not offered to patients in the PATCH trial because it was felt to potentially cause tissue damage without reliably relieving pain. Prevention before gynecomastia develops is preferable if this is a significant concern for you.
Cost and Accessibility
Dr. James has repeatedly underscored the economic dimension of this finding. LHRH agonist injections are expensive — often running thousands of dollars per injection in the U.S. Transdermal estradiol patches, by contrast, are generic drugs widely available at pharmacies for a fraction of the cost. The Estradiol Initiative notes that estradiol gel can be obtained through commercial products (Estrogel, Divigel) or compounding pharmacies with a physician's prescription. This could be transformative for patients who are cost-sharing for newer combination therapies, and for access in resource-limited settings worldwide.
Practical Considerations: How Does It Work?
The PATCH protocol uses multiple high-dose patches (releasing 100 mcg/24 hours each) applied to the abdomen, hips, or upper buttocks, changed twice weekly. Three or four patches are typically applied simultaneously to achieve the estradiol levels needed to suppress testosterone. Serum testosterone and estradiol levels are monitored and dosing is adjusted individually, as there is significant variation in absorption between patients. It takes approximately 3–4 weeks of continuous use to reach steady-state estradiol levels.
Unlike LHRH agonists, estradiol does not cause an initial testosterone "flare" at the start of therapy, which is a meaningful advantage — LHRH agonist starters often require a short course of anti-androgens to cover that flare. With patches, that additional medication step is generally not needed.
An Open Question: Do We Need Testosterone Suppression at All?
At the ASCO GU 2025 symposium, an intriguing question was raised from the audience: given that enzalutamide (Xtandi) plus an LHRH agonist and enzalutamide plus an estradiol patch appear to perform similarly, is the testosterone suppression component actually necessary, or is the androgen receptor inhibitor doing all the work? Dr. James acknowledged this was a genuinely interesting and open research question: "Can we drop the testosterone suppression completely? That's something we should pursue much more." This is an area to watch for future trial results.
📖 Glossary of Key Terms
- ADT (Androgen Deprivation Therapy)
- Treatment that lowers testosterone to slow prostate cancer growth. The "backbone" of treatment for advanced disease.
- LHRH Agonist
- Drugs (e.g., leuprolide/Lupron, goserelin/Zoladex) that suppress testosterone production via the brain's hormone signaling pathway. The current standard for ADT.
- Transdermal Estradiol (tE2)
- Estradiol (a natural estrogen) delivered through a skin patch. Bypasses the liver, avoiding the blood-clotting risk of older oral estrogen.
- Metastasis-Free Survival (MFS)
- The percentage of patients alive and free of cancer spread after a defined period (here, 3 years).
- Non-Inferiority
- A statistical standard proving a new treatment is not meaningfully worse than the existing standard of care — it doesn't have to be better, just not worse by a meaningful margin.
- ARPI (Androgen Receptor Pathway Inhibitor)
- Drugs (e.g., enzalutamide/Xtandi, abiraterone/Zytiga, apalutamide/Erleada) that block testosterone from stimulating cancer cell growth at the receptor level.
- Gynecomastia
- Swelling and tenderness of breast tissue, a known side effect of estrogen-related therapies. Can range from mild to more pronounced.
- Castrate Testosterone Level
- A testosterone level below 50 ng/dL, the target threshold for effective ADT.
- PATCH Trial
- Prostate Adenocarcinoma TransCutaneous Hormone trial — the 15-year UK study evaluating estradiol patches as ADT, merged into the STAMPEDE platform trial.
- STAMPEDE Trial
- Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy — a large multi-arm platform trial that has evaluated multiple treatment strategies for advanced prostate cancer.
💬 Questions to Ask Your Doctor
- Am I a candidate for transdermal estradiol patches instead of — or in addition to — my current hormone injections?
- Given my cardiovascular history, would estradiol patches be safer for me than LHRH agonist injections?
- How is my bone density? Have I had a DEXA scan? Could patches help protect my bones?
- If I switch to patches, how would we monitor my testosterone and PSA?
- Should I consider prophylactic breast bud radiation or tamoxifen before starting patches to prevent gynecomastia?
- Are estradiol patches available and covered by my insurance in the United States?
- If I am on Xtandi/abiraterone, could the patches replace my Lupron/Zoladex injection?
What This Means for IPCSG Members
For members of this support group — many of whom are managing the demanding side effects of long-term ADT — these findings carry real practical meaning. Hot flashes are not a minor inconvenience; they disrupt sleep, impair cognition, and undermine quality of life every single day. Bone fractures from long-term ADT can be life-altering. Cardiovascular risk is a serious concern for older men. The estradiol patch addresses all three of these problems while controlling cancer just as effectively as the current standard of care.
The tradeoff — a meaningfully higher rate of gynecomastia — is real and should be discussed honestly with your physician. But gynecomastia is also not inevitable; prophylactic strategies exist. And for some men, trading hot flashes for manageable breast changes is a clear and acceptable exchange.
These results will now enter guideline review processes at ASCO, the European Association of Urology, and the NCCN. Expect this option to appear in formal treatment guidelines in the coming year. In the meantime, given the strength of the NEJM publication, a well-informed conversation with your oncologist about suitability is entirely appropriate today.
The Bottom Line
After 15 years and 1,360 patients, the verdict is in: a simple, inexpensive skin patch can do the job of an expensive monthly injection — equally well, with a better side-effect profile for many men. This is a meaningful expansion of patient choice in prostate cancer hormone therapy. Ask your doctor whether estradiol patches belong in your treatment plan.
Verified Sources & Formal Citations
- PATCH/STAMPEDE Phase III — Primary NEJM Publication (March 2026):
Langley RE, et al. "Transdermal Estradiol Patches in Locally Advanced Prostate Cancer." New England Journal of Medicine. Published March 25, 2026. DOI: 10.1056/NEJMoa2511781.
https://www.nejm.org/doi/full/10.1056/NEJMoa2511781 - MedPage Today — Primary News Coverage (March 2026):
Bankhead C. "Estradiol Patch Matches LHRH Agonists for Locally Advanced Prostate Cancer." MedPage Today. March 25, 2026.
https://www.medpagetoday.com/ - STAMPEDE M1 Sub-Study — ASCO GU 2025 Abstract:
James ND, et al. "Transdermal Oestradiol (tE2) patches as androgen deprivation therapy (ADT): Efficacy and safety of combining with androgen receptor pathway inhibitors (ARPIs) in metastatic (M1) prostate cancer—Randomised comparison from the STAMPEDE trial platform." Journal of Clinical Oncology 43, 5_suppl, 21–21 (2025).
https://ascopubs.org/doi/10.1200/JCO.2025.43.5_suppl.21 - ASCO Daily News — ASCO GU 2025 Coverage:
"Transdermal Estrogen May Offer Another Option for ADT in Men With Metastatic Prostate Cancer." ASCO Daily News. February 10, 2025.
https://dailynews.ascopubs.org/do/transdermal-estrogen-may-offer-another-option-adt-men-metastatic-prostate-cancer - UroToday — ASCO GU 2025 Presentation Summary:
Sayyid RK. "ASCO GU 2025: Transdermal Oestradiol Patches as ADT: Efficacy and Safety of Combining with ARPIs in Metastatic (M1) Prostate Cancer—Randomised Comparison from the STAMPEDE Trial Platform." UroToday. February 15, 2025.
https://www.urotoday.com/conference-highlights/asco-gu-2025/asco-gu-2025-prostate-cancer/158247 - OncLive — ASCO GU 2025 Coverage:
"Transdermal Estradiol Plus ARPIs Demonstrate Comparable PSA Response to LHRHa in Metastatic Prostate Cancer." OncLive. February 2025.
https://www.onclive.com/view/transdermal-estradiol-plus-arpis-demonstrate-comparable-psa-response-to-lhrha-in-metastatic-prostate-cancer - PATCH Programme Overview — ScienceDirect (2023):
Langley RE, et al. "A Repurposing Programme Evaluating Transdermal Oestradiol Patches for the Treatment of Prostate Cancer Within the PATCH and STAMPEDE Trials: Current Results and Adapting Trial Design." Cancer Treatment Reviews. November 2023.
https://www.sciencedirect.com/science/article/pii/S0936655523003953 - PATCH Cardiovascular Long-Term Outcomes — PMC:
Langley RE, et al. "Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme." The Lancet Oncology. PMC7614681.
https://pmc.ncbi.nlm.nih.gov/articles/PMC7614681/ - Urology Times — Evidence and Impact Summary (February 2026):
"Estradiol Patches in Prostate Cancer: Evidence and Impact." Urology Times. February 21, 2026.
https://www.urologytimes.com/view/estradiol-patches-in-prostate-cancer-evidence-and-impact - Medscape — ASCO GU 2025 Coverage (February 2025):
"Estradiol Patches Safe, Effective in Prostate Cancer." Medscape. February 20, 2025.
https://www.medscape.com/viewarticle/estradiol-patches-safe-effective-prostate-cancer-2025a10004ft - UroToday Video — PATCH Trial Overview, Dr. Duncan Gilbert (ESMO 2024):
"PATCH Trial Evaluates Transdermal Estradiol in Non-Metastatic Prostate Cancer." UroToday. September 26, 2024.
https://www.urotoday.com/video-lectures/localized-prostate-cancer/video/4308-patch-trial-evaluates-transdermal-estradiol - UroToday — Estrogen Patches + ARPIs Video Interview, Dr. Nicholas James (ASCO GU 2025):
"Estrogen Patches Combined with AR Pathway Inhibitors Show Promise in Prostate Cancer Management." UroToday. February 2025.
https://www.urotoday.com/categories-media/1748-centers-of-excellence/advanced-prostate-cancer-coe/4647 - Estrogen Deficiency in Men on ADT — Journal of the Endocrine Society (2024):
"Loss of Estradiol by Androgen Deprivation in Prostate Cancer Patients Shows the Importance of Estrogens in Males." Journal of the Endocrine Society. May 23, 2024. DOI: 10.1210/jendso/bvae107.
https://academic.oup.com/jes/article/8/7/bvae107/7687567 - Gynecomastia Prevention — European Urology Open Science Meta-Analysis (2025):
"Incidence, Management, and Prevention of Gynecomastia and Breast Pain in Patients with Prostate Cancer Undergoing Antiandrogen Therapy." European Urology Open Science. Volume 72, 2025.
https://www.sciencedirect.com/science/article/pii/S2666168325000114 - Prophylactic Breast Irradiation — Scandinavian Trial (SPCG-7/SFUO-3):
Widmark A, Fosså SD, Lundmo P, et al. "Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3." Urology. 2003; 61(1):145–151. PMID: 12559286.
https://pubmed.ncbi.nlm.nih.gov/12559286/ - Estradiol Initiative — Administration and Practical Guidance:
"Administration Consideration for tE2 Products." Estradiol Initiative. Accessed March 2026.
https://estradiolinitiative.org/research/administration-consideration-for-te2-products/ - PCa Commentary #201 — PATCH Trial Update and tE2 Usage:
"PCa Commentary #201 – Update of the Patch Trial and Information About Transdermal Estradiol Usage." ProstateCancerFree.org. June 23, 2025.
https://www.prostatecancerfree.org/pca-commentary-201- - Targeted Oncology — ASCO GU 2025 Coverage:
"Estradiol and Hormone Therapy Show Similar PSA Response in Prostate Cancer." Targeted Oncology. February 2025.
https://www.targetedonc.com/view/estradiol-and-hormone-therapy-show-similar-psa-response-in-prostate-cancer
Comments
Post a Comment